Johns Hopkins

Report: Feds, Big Pharma Likely to Reduce Research Funding

Two Johns Hopkins faculty members predict drug developers may need to innovate to find other funding.

In a commentary to be published in the Dec. 12 issue of The Journal of the American Medical Association, two Johns Hopkins faculty members predict an ever-diminishing role for government and drug company funding of basic biomedical research and suggest scientists look to 'innovative' kinds of private investment for future resources.

Current negotiations in Washington over sequestration and the so-called 'fiscal cliff' provide an opportunity to fundamentally rethink the funding of biomedical research, they say.

No votes yet
Syndicate content